CMS D001
Alternative Names: CMS-D001Latest Information Update: 17 Jun 2026
At a glance
- Originator China Medical System; Dermavon
- Class Antipsoriatics; Skin disorder therapies; Small molecules
- Mechanism of Action TYK2 kinase inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Plaque psoriasis
- Phase II Atopic dermatitis
Most Recent Events
- 20 Mar 2026 Phase-II clinical trials in Atopic dermatitis (Treatment-experienced) in China (PO) (NCT07465120) (Dermavon pipeline, June 2026)
- 11 Mar 2026 Dermavon Holdings Limited plans a phase II trial for Atopic dermatitis (Treatment-resistant) in China (PO, tablet) in March 2026 (NCT07465120)
- 03 Mar 2026 Phase-II/III clinical trials in Plaque psoriasis in China (PO) (NCT07432854) (Dermavon pipeline, June 2026)